AUTHORS
Li Wang III, MD, Yaohui Huang Jr2, Xiaofeng Luo3, Jing Bao4, Yang Shen, PhD5, Li Chen, MD6, Bing-bing Zhao7, Jing Wang8, Xiaozhong Shen9, Lu Jiang10, Yan Huang11, Song-fu Jiang12, Lin Shen13, Xin Li, MD, PhD14, Jingjing Ye15, Pengpeng Xu, MD16, Shu Cheng, MD17, Jianzhen Shen18, Wei Li Zhao III, Certified Doctor19
AFFILIATIONS
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fujian, China
4 The First Affiliated Hospital of Anhui Medical University, Anhui, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 Shanghai 411 Hospital, Shanghai, China
8 Yangpu Hospital, Tongji University School of Medicine, Shanghai, China
9 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 The First People’s Hospital of Jiujiang, Jiujiang, China
12 the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
13 Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China
14 The Third Xiangya Hospital of Central South University, Changsha, China
15 Qilu Hospital of Shandong University, Shandong, China
16 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, Shanghai, China
17 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, Shanghai, China
18 Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fujian, China
19 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, Shanghai, China
ABSTRACT
Background
Patients (pts) with high-risk mantle cell lymphoma (MCL), including those with TP53 abnormalities, blastoid/pleomorphic morphology, high proliferative index, or high-risk MIPI, continue to have poor outcomes with conventional chemoimmunotherapy. Although Bruton tyrosine kinase inhibitors (BTKis) have improved frontline treatment, pts with TP53-aberrant or blastoid MCL remain at high risk of early relapse. Chemotherapy-free combinations targeting BTK and BCL2 have shown promising efficacy in high-risk MCL. Orelabrutinib is a highly selective next-generation BTKi with a favorable safety profile, while lisaftoclax is a novel BCL2 inhibitor with potent antitumor activity. Their combination may provide synergistic antitumor effects while avoiding chemotherapy-related toxicity. We therefore conducted a prospective, multicenter phase II study to evaluate orelabrutinib, rituximab, and lisaftoclax (ORL) as frontline chemo-free therapy for newly diagnosed high-risk MCL.
Aims
To evaluate the efficacy and safety of chemo-free ORL induction followed by OL maintenance in newly diagnosed high-risk MCL.
Methods
This is an ongoing prospective, multicenter, open-label, single-arm phase II study conducted across ten centers in China (NCT07272499). Eligible pts were newly diagnosed MCL requiring systemic therapy and possessed at least one predefined high-risk feature, including TP53 mutation or deletion, blastoid or pleomorphic morphology, or high-risk MIPI-b. Pts received six 28-day induction cycles consisting of lisaftoclax (600 mg daily following dose ramp-up), orelabrutinib (150 mg once daily), and rituximab (375 mg/m²). Pts achieving complete or partial remission proceeded to maintenance therapy with orelabrutinib and lisaftoclax for two years. Tumor lysis syndrome prophylaxis and monitoring were prospectively implemented according to protocol.
The primary endpoint was best complete response (CR) during induction according to the Lugano 2014 criteria. Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), safety, and pharmacokinetic characteristics of lisaftoclax.
Results
At the data cutoff, 25 pts had been enrolled and comprised the safety population. Twenty-four pts were evaluable for efficacy. Median age was 68 years (range, 45–84), and 72.0% were male. This represented a biologically high-risk population, with TP53 mutations present in 36.0%, blastoid morphology in 20.0%, bone marrow involvement in 76.0%, elevated LDH in 40.0%, and Ki-67 ≥30% in 76.0% of pts.
ORL produced rapid and deep responses. Among the 24 pts who underwent interim response assessment, 22 (91.7%) achieved a metabolic response, including 15 (62.5%) with complete metabolic response (CMR) and 7 (29.2%) with partial metabolic response (PMR). Two pts (8.3%) had stable metabolic disease (SMD), and no pt developed progressive metabolic disease during induction. Responses were maintained across all predefined high-risk subgroups. Among pts with TP53 mutations, ORR and CMR rates were 88.9% and 77.8%, respectively, compared with 92.9% and 50.0% among TP53 wild-type pts. Pts with blastoid morphology achieved an ORR of 80.0% and CMR rate of 40.0%. No statistically significant differences in ORR or CMR were observed according to age, sex, ECOG performance status, LDH level, baseline leukocyte count, Ki-67 index, bone marrow involvement, TP53 status, or blastoid morphology, suggesting consistent activity across adverse biological subsets.
Treatment was generally well tolerated. At the data cutoff, the most common hematologic adverse events were anemia (52.0%), neutropenia (44.0%), and thrombocytopenia (40.0%). Grade ≥3 neutropenia and thrombocytopenia each occurred in only one pt (4.0%), while no grade ≥3 anemia was observed.
Conclusion
This prospective multicenter phase II study demonstrates that frontline chemo-free therapy with orelabrutinib, rituximab, and lisaftoclax is highly active and well tolerated in newly diagnosed high-risk mantle cell lymphoma. These interim findings suggest that dual targeting of BTK and BCL2, combined with anti-CD20 immunotherapy, represents a promising chemo-free frontline strategy in biologically aggressive MCL. Longer follow-up will determine whether these encouraging early responses translate into durable progression-free survival and establish ORL as a potential frontline treatment option for pts with high-risk MCL.
DISCLOSURES
Li Wang III, MD: No relevant conflicts of interest to declare.